Onconetix Inc. (NASDAQ:ONCO) shares soared 23.65% to $0.38 in after-hours trading on Monday.
The Ohio-based biotechnology company reversed a steep 18.26% regular session decline, closing the stock at $0.31, according to Benzinga Pro data.
Clinical Validation
On May 13, Onconetix reported first-quarter 2026 operational progress from its fully-owned Swiss subsidiary, Proteomedix AG, developer of Proclarix, a CE-IVD certified blood test designed to identify clinically significant prostate cancer in combination with prostate-specific antigen (PSA) testing.
Prostate cancer is the most commonly diagnosed cancer in men in most countries around the world and places a significant burden on patients and healthcare systems.
A National Institutes of Health 2019 report found that in 2018, over 1 million new cases of prostate cancer were reported globally, accounting for 7.1% of all cancers diagnosed in men.
According to the …
